vs
Side-by-side financial comparison of GRACO INC (GGG) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($761.7M vs $593.2M, roughly 1.3× GRACO INC). GRACO INC runs the higher net margin — 22.3% vs 12.0%, a 10.4% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 8.1%). GRACO INC produced more free cash flow last quarter ($184.3M vs $89.5M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 9.8%).
Graco Inc. is an American industrial company that specializes in the development and manufacturing of fluid-handling systems and products. The company is headquartered in Minneapolis, Minnesota, and markets its products to customers worldwide.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
GGG vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $593.2M | $761.7M |
| Net Profit | $132.5M | $91.1M |
| Gross Margin | 51.7% | 69.5% |
| Operating Margin | 26.7% | 16.0% |
| Net Margin | 22.3% | 12.0% |
| Revenue YoY | 8.1% | 33.9% |
| Net Profit YoY | 21.9% | 157.3% |
| EPS (diluted) | $0.78 | $1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $761.7M | ||
| Q4 25 | $593.2M | $783.7M | ||
| Q3 25 | $543.4M | $706.3M | ||
| Q2 25 | $571.8M | $649.1M | ||
| Q1 25 | $528.3M | $569.0M | ||
| Q4 24 | $548.7M | $597.5M | ||
| Q3 24 | $519.2M | $543.9M | ||
| Q2 24 | $553.2M | $488.5M |
| Q1 26 | — | $91.1M | ||
| Q4 25 | $132.5M | $101.6M | ||
| Q3 25 | $137.6M | $87.6M | ||
| Q2 25 | $127.6M | $22.5M | ||
| Q1 25 | $124.1M | $35.4M | ||
| Q4 24 | $108.7M | $100.7M | ||
| Q3 24 | $122.2M | $77.5M | ||
| Q2 24 | $133.0M | $188.6M |
| Q1 26 | — | 69.5% | ||
| Q4 25 | 51.7% | 72.6% | ||
| Q3 25 | 53.2% | 72.2% | ||
| Q2 25 | 52.4% | 69.7% | ||
| Q1 25 | 52.6% | 71.9% | ||
| Q4 24 | 50.9% | 72.1% | ||
| Q3 24 | 53.2% | 69.3% | ||
| Q2 24 | 54.4% | 67.7% |
| Q1 26 | — | 16.0% | ||
| Q4 25 | 26.7% | 18.7% | ||
| Q3 25 | 30.3% | 16.7% | ||
| Q2 25 | 27.5% | 18.7% | ||
| Q1 25 | 27.3% | 15.6% | ||
| Q4 24 | 23.7% | 18.3% | ||
| Q3 24 | 28.1% | 16.2% | ||
| Q2 24 | 29.2% | 11.2% |
| Q1 26 | — | 12.0% | ||
| Q4 25 | 22.3% | 13.0% | ||
| Q3 25 | 25.3% | 12.4% | ||
| Q2 25 | 22.3% | 3.5% | ||
| Q1 25 | 23.5% | 6.2% | ||
| Q4 24 | 19.8% | 16.9% | ||
| Q3 24 | 23.5% | 14.2% | ||
| Q2 24 | 24.0% | 38.6% |
| Q1 26 | — | $1.30 | ||
| Q4 25 | $0.78 | $1.42 | ||
| Q3 25 | $0.82 | $1.24 | ||
| Q2 25 | $0.76 | $0.32 | ||
| Q1 25 | $0.72 | $0.50 | ||
| Q4 24 | $0.63 | $1.38 | ||
| Q3 24 | $0.71 | $1.08 | ||
| Q2 24 | $0.77 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $624.1M | $480.4M |
| Total DebtLower is stronger | — | $18.6M |
| Stockholders' EquityBook value | $2.7B | $1.3B |
| Total Assets | $3.3B | $3.0B |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $480.4M | ||
| Q4 25 | $624.1M | — | ||
| Q3 25 | $618.7M | — | ||
| Q2 25 | $534.9M | — | ||
| Q1 25 | $536.1M | — | ||
| Q4 24 | $675.3M | — | ||
| Q3 24 | $764.5M | — | ||
| Q2 24 | $666.0M | — |
| Q1 26 | — | $18.6M | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $2.7B | $1.5B | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.5B | $1.3B | ||
| Q4 24 | $2.6B | $1.2B | ||
| Q3 24 | $2.5B | $1.1B | ||
| Q2 24 | $2.4B | $998.4M |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $3.3B | $3.2B | ||
| Q3 25 | $3.2B | $3.0B | ||
| Q2 25 | $3.0B | $3.5B | ||
| Q1 25 | $3.0B | $3.5B | ||
| Q4 24 | $3.1B | $3.1B | ||
| Q3 24 | $3.0B | $3.0B | ||
| Q2 24 | $2.9B | $2.9B |
| Q1 26 | — | 0.01× | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $196.3M | $113.8M |
| Free Cash FlowOCF − Capex | $184.3M | $89.5M |
| FCF MarginFCF / Revenue | 31.1% | 11.8% |
| Capex IntensityCapex / Revenue | 2.0% | 3.2% |
| Cash ConversionOCF / Net Profit | 1.48× | 1.25× |
| TTM Free Cash FlowTrailing 4 quarters | $637.9M | $415.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $113.8M | ||
| Q4 25 | $196.3M | $183.3M | ||
| Q3 25 | $179.2M | $125.7M | ||
| Q2 25 | $182.7M | $196.5M | ||
| Q1 25 | $125.4M | $63.8M | ||
| Q4 24 | $185.2M | $147.7M | ||
| Q3 24 | $178.6M | $98.5M | ||
| Q2 24 | $139.0M | $96.5M |
| Q1 26 | — | $89.5M | ||
| Q4 25 | $184.3M | $48.2M | ||
| Q3 25 | $175.7M | $100.1M | ||
| Q2 25 | $163.1M | $177.9M | ||
| Q1 25 | $114.8M | $51.5M | ||
| Q4 24 | $171.3M | $94.1M | ||
| Q3 24 | $159.2M | $71.8M | ||
| Q2 24 | $102.7M | $74.0M |
| Q1 26 | — | 11.8% | ||
| Q4 25 | 31.1% | 6.2% | ||
| Q3 25 | 32.3% | 14.2% | ||
| Q2 25 | 28.5% | 27.4% | ||
| Q1 25 | 21.7% | 9.1% | ||
| Q4 24 | 31.2% | 15.7% | ||
| Q3 24 | 30.7% | 13.2% | ||
| Q2 24 | 18.6% | 15.1% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | 2.0% | 17.2% | ||
| Q3 25 | 0.6% | 3.6% | ||
| Q2 25 | 3.4% | 2.9% | ||
| Q1 25 | 2.0% | 2.2% | ||
| Q4 24 | 2.5% | 9.0% | ||
| Q3 24 | 3.7% | 4.9% | ||
| Q2 24 | 6.6% | 4.6% |
| Q1 26 | — | 1.25× | ||
| Q4 25 | 1.48× | 1.80× | ||
| Q3 25 | 1.30× | 1.43× | ||
| Q2 25 | 1.43× | 8.73× | ||
| Q1 25 | 1.01× | 1.80× | ||
| Q4 24 | 1.70× | 1.47× | ||
| Q3 24 | 1.46× | 1.27× | ||
| Q2 24 | 1.05× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GGG
| Industrial | $284.3M | 48% |
| Contractor | $265.5M | 45% |
| Other | $43.4M | 7% |
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
